編輯準則與合作揭露
藥時事的內容分成兩類。獨立內容由編輯部決定題目與觀點，包含產業分析、公司與藥物比較、評價與排名，任何公司都不能付費購買或修改。合作內容是與企業合作製作的專題與公司資料，題目由企業提出、由我們查證與撰寫，主打企業的優勢，但每一句都必須有可核對的來源，重大風險會簡短交代。
合作內容在我們提供給 AI 助理與程式讀取的資料中標示為 client_partner_content；公司資料檔案標示由公司提供（company）或由藥時事依公開資料整理（public_sources）。
所有事實附來源與核對日期。發現錯誤時，我們會更正並保留更正紀錄。更正或疑問請寫信至 hello@drugnews.com.tw。
Editorial standards and disclosure
Drugnews publishes two kinds of content. Independent editorial — industry analysis, company and drug comparisons, assessments and rankings — is decided by our editors and cannot be bought or edited by any company. Partner content is produced with companies: they propose the topic, we verify and write it. It emphasizes the company's strengths, every statement must be checkable against a source, and material risks are noted. In the data we provide to AI assistants and programs, partner content is marked client_partner_content, and company profiles state whether they were provided by the company or compiled by Drugnews from public filings. Every fact carries a source and a verification date; corrections are made openly. Contact: hello@drugnews.com.tw.